Clinical Trial Update: Efficacy and Safety of Intracoronary Ad5FGF-4 in Patients With Stable Angina (AGENT-3) [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update reports on the efficacy and safety of intracoronary Ad5FGF-4 in patients with stable angina (AGENT-3) across Phase 2 and Phase 3; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stable Angina

Drugs mentioned

• Ad5FGF-4 (adenovirus type 5 fibroblast growth factor-4 gene therapy)

Snippet

Sponsor: Cardium Therapeutics | Conditions: Angina Pectoris | Phase 2, Phase 3 | Status: COMPLETED